Open Payments

Valley Childrens Hospital

Type
Teaching hospital
Where
MADERA, CA
Medicare CCN
053300
Received
$171,833 in 38 records, 2025 ($30,665 general, $141,168 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2025General payment19$30,665
2025Research payment19$141,168

By company

CompanyRecordsAmountYears
ABBVIE INC.4$65,8032025
Genentech, Inc.6$36,1532025
Novartis Pharmaceuticals Corporation4$12,7862025
MED-EL Corporation1$9,0902025
Abbott Laboratories1$8,9502025
SpringWorks Therapeutics, Inc.3$7,5002025
VERTEX PHARMACEUTICALS INCORPORATED1$6,5002025
HEMA Biologics, LLC1$5,6752025
Neurelis, Inc.3$5,5002025
PFIZER INC.1$4,8002025
Sarepta Therapeutics, Inc.1$1,5002025
NS Pharma, Inc.1$1,5002025
Siemens Medical Solutions USA, Inc.1$1,2242025
E.R. Squibb & Sons, L.L.C.1$1,0002025
Alexion Pharmaceuticals, Inc.1$1,0002025
Incyte Corporation1$1,0002025
JAZZ PHARMACEUTICALS INC.1$9002025
SANOFI-AVENTIS U.S. LLC1$7502025
Stryker Corporation1$1182025
Bio-Rad Laboratories, Inc.2$382025
Smith+Nephew, Inc.1$302025
WERFEN USA LLC1$132025

By nature of payment

NatureRecordsAmount
Research payment19$141,168
Grant5$10,500
Long term medical supply or device loan3$10,344
Education3$5,500
Space rental or facility fees (teaching hospital only)3$3,150
Gift1$1,000
Debt forgiveness4$170

Records

DateCompanyAmountNatureFormProductStudyYear
2025-12-31Stryker Corporation$118Debt forgivenessCash or cash equivalent2025
2025-12-03SpringWorks Therapeutics, Inc.$2,500GrantCash or cash equivalentGOMEKLI Drug2025
2025-11-05PFIZER INC.$4,800Research paymentCash or cash equivalentLORBRENA Drug, ONCOLOGYANBL1531 LORLATINIB ARM A PHASE 3 STUDY OF 131IMETAIODOBENZYLGUANIDINE 131IMIBG OR ALK INHIBITOR THERAPY ADDED TO INTEN2025
2025-10-25VERTEX PHARMACEUTICALS INCORPORATED$6,500Research paymentCash or cash equivalentA Non-Interventional Study Evaluating the Impact of TRIKAFTA Initiation on 2- to 5-Year-Olds With Cystic Fibrosis and Th2025
2025-10-22Genentech, Inc.$633Research paymentCash or cash equivalentEvrysdi Drug, NeurologyLONG TERM FOLLOW UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT2025
2025-10-02ABBVIE INC.$416Research paymentIn-kind items and servicesVENCLEXTA Drug, ONCOLOGYPilot Study of Venetoclax in Combination with Conventional Chemotherapy in Pediatric Patients with Acute Myeloid Leukemi2025
2025-10-01Novartis Pharmaceuticals Corporation$150Research paymentCash or cash equivalentZOLGENSMA Drug, NeurologyA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2025
2025-09-25WERFEN USA LLC$13Debt forgivenessCash or cash equivalent2025
2025-08-20Siemens Medical Solutions USA, Inc.$1,224Long term medical supply or device loanIn-kind items and services2025
2025-07-24SpringWorks Therapeutics, Inc.$2,500GrantCash or cash equivalentGOMEKLI Drug2025
2025-07-17Smith+Nephew, Inc.$30Long term medical supply or device loanIn-kind items and servicesACUFEX Device, Sports Med Shoulder2025
2025-07-16Genentech, Inc.$1,899Research paymentCash or cash equivalentLONG TERM FOLLOW UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT2025
2025-07-09Novartis Pharmaceuticals Corporation$3,360Research paymentCash or cash equivalentZOLGENSMA Drug, NeurologyA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2025
2025-06-25MED-EL Corporation$9,090Long term medical supply or device loanIn-kind items and servicesMi1250 SYNCHRONY 2 FLEXsoft Device, Cochlear Implant2025
2025-05-22SpringWorks Therapeutics, Inc.$2,500GrantCash or cash equivalentGOMEKLI Drug2025
2025-05-15HEMA Biologics, LLC$5,675Research paymentCash or cash equivalentSEVENFACT Drug, HEMATOLOGYRetrospective Experience Assessing the Real-World Utilization and Effectiveness of SEVENFACT2025
2025-05-14E.R. Squibb & Sons, L.L.C.$1,000Research paymentCash or cash equivalentRisk adapted, response based Phase 2 trial of nivolumab and brentuximab vedotin followed by brentuximab vedotin and bend2025
2025-04-26Novartis Pharmaceuticals Corporation$1,500Space rental or facility fees (teaching hospital only)Cash or cash equivalentZOLGENSMA Drug, Neurology2025
2025-04-24Alexion Pharmaceuticals, Inc.$1,000GiftCash or cash equivalent2025
2025-04-22Sarepta Therapeutics, Inc.$1,500GrantCash or cash equivalent2025
2025-04-18Bio-Rad Laboratories, Inc.$19Debt forgivenessCash or cash equivalentLiquichek Device, Controls2025
2025-04-18Bio-Rad Laboratories, Inc.$19Debt forgivenessCash or cash equivalentLipid Transfection Reagents Device, Not Applicable2025
2025-04-16Neurelis, Inc.$3,500EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2025
2025-04-04SANOFI-AVENTIS U.S. LLC$750Space rental or facility fees (teaching hospital only)Cash or cash equivalentTZIELD Biological, Endocrine & Metabolic Diseases2025
2025-04-02NS Pharma, Inc.$1,500GrantCash or cash equivalentVILTEPSO Drug, PEDIATRIC NEUROLOGY2025
2025-04-01Incyte Corporation$1,000Research paymentCash or cash equivalentA Phase 2 Study of the JAK1, JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High Risk CRLF2 Rearr2025
2025-04-01Neurelis, Inc.$1,000EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2025
2025-03-17Neurelis, Inc.$1,000EducationCash or cash equivalentVALTOCO Drug, EPILEPSY2025
2025-03-12Novartis Pharmaceuticals Corporation$7,775Research paymentCash or cash equivalentZOLGENSMA Drug, NeurologyA Prospective, Long-Term Registry of Patients with a Diagnosis of Spinal Muscular Atrophy2025
2025-02-13Genentech, Inc.$21,000Research paymentCash or cash equivalentRisdiplam post gene therapy study plateau symptoms study 22025
2025-02-12Genentech, Inc.$11,988Research paymentCash or cash equivalentLONG TERM FOLLOW UP STUDY OF PATIENTS WITH SPINAL MUSCULAR ATROPHY RECEIVING RISDIPLAM TREATMENT2025
2025-02-12Genentech, Inc.$560Research paymentCash or cash equivalentEvrysdi Drug, NeurologyEarly Model for Satralizumab in Generalized Myasthenia Gravis2025
2025-02-12Genentech, Inc.$73Research paymentCash or cash equivalentEvrysdi Drug, NeurologyPost Marketing Surveillance of VABYSMO2025
2025-01-30ABBVIE INC.$2,082Research paymentIn-kind items and servicesVENCLEXTA Drug, ONCOLOGYA23-488;Venclexta;Blister Card: ABT-199 50mg Film-coated Tablet 1x8, 8 Tablets2025
2025-01-30ABBVIE INC.$832Research paymentIn-kind items and servicesVENCLEXTA Drug, ONCOLOGYA23-488;Venclexta;Blister Card: ABT-199 10mg Tablet 2x8, 16 Tablets2025
2025-01-16ABBVIE INC.$62,472Research paymentIn-kind items and servicesVENCLEXTA Drug, ONCOLOGYA23-488;Venclexta;Bottle: ABT-199 100mg Yellow Film Coated Tablet 120 Tablets2025
2025-01-13Abbott Laboratories$8,950Research paymentCash or cash equivalentSJM MASTERS SERIES Device, Structural HeartNCT02097420--HALO: A Single Arm Prospective Investigation of the SJM Masters HP 15mm Rotatable Mechanical Heart Valve2025
2025-01-10JAZZ PHARMACEUTICALS INC.$900Space rental or facility fees (teaching hospital only)Cash or cash equivalent2025

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Madera CountyMadera city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Madera, CA, county Madera County, CA, state California; placed by its city name.

MeasurePlace (city or town)
Madera, CA
County
Madera County, CA
State
California
Population B0100367,831160,94039,287,377
Population, 2020 census P166,224156,25539,538,223
Median age B0100230.434.637.9
Under 18 B0100130.8%27.1%22.0%
65 and over B010019.6%14.4%15.7%
Households B1100117,52645,37913,548,091
Foreign born B0500225.6%20.1%27.0%
Median household income B19013$63,933$76,627$99,122
Median family income B19113$67,479$83,389$113,346
Per capita income B19301$24,200$30,077$49,513
Poverty rate B1700125.6%19.2%12.0%
Unemployment rate B2302512.6%10.1%6.6%
Civilian labor force B2302529,99769,01220,068,466
Mean commute (minutes) B0801325.727.928.7
Bachelor's degree or higher B1500310.9%17.9%37.1%
Housing units B2500118,56251,01514,644,735
Owner-occupied B2500354.7%67.5%55.9%
Renters B2500345.3%32.5%44.1%
Median home value B25077$359,900$393,200$734,700
Median gross rent B25064$1,353$1,390$2,036
White, not Hispanic B0300212.2%29.9%33.8%
Black B030022.9%2.4%5.2%
Hispanic or Latino B0300281.1%60.9%40.2%
Asian B030021.3%2.4%15.3%
American Indian and Alaska Native B030020.1%0.4%0.3%

Economy now FRED unemployment 5.1% in Sep 2026 (5.5% a year earlier); per capita personal income $90,957 in 2025, up 30% in five years (+4.3% after inflation); Unemployment rate: 5.5% in Sep 2016 to 5.1% in Sep 2026; low 3.8%, high 16.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Madera, CA.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.